ClinConnect ClinConnect Logo
Search / Trial NCT06954532

ADIE-BC - Aligning Dimensions of Interoceptive Experience in Breast Cancer Survivors

Launched by KING'S COLLEGE LONDON · Apr 24, 2025

Trial Information

Current as of August 21, 2025

Recruiting

Keywords

Breast Cancer Primary Breast Cancer Adie Therapy Biobehavioral Medicine Anxiety Management Interoception Emotion Regulation Interoceptive Training Cardiac Interoception Mind Body Therapy

ClinConnect Summary

The ADIE-BC trial is studying a new type of therapy called ADIE Therapy, which aims to help breast cancer survivors manage anxiety. Many people who have been treated for breast cancer continue to feel anxious long after their treatment ends. This anxiety can be tied to how they perceive their bodies and their feelings, a process called interoception. The trial will assess how acceptable and feasible this therapy is for breast cancer survivors, helping them better recognize their bodily signals and potentially reduce their anxiety.

To be eligible for this study, participants must be at least 18 years old, living in the UK, and able to travel to London for sessions. They should have been diagnosed with primary breast cancer and have completed their active treatment (like surgery or chemotherapy) between 6 months and 10 years ago. Participants should be comfortable reading and writing in English. They cannot be currently pregnant or undergoing treatment for breast cancer or other cancers. If you join the trial, you can expect to learn more about your body’s signals and how to manage anxiety in a supportive environment. This study is not yet recruiting participants, but it's an important step towards helping breast cancer survivors feel better.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 18 years old or older
  • Residing in the UK and able to travel into London
  • Can read and write in English
  • Have had a diagnosis of Primary Breast Cancer
  • Have completed active, hospital-based treatment for primary breast cancer (Stages 1, 2 or 3; this refers to radiotherapy, surgery, or chemotherapy) 6 months - 10 years previously (this does not apply to ongoing endocrine (hormone) therapy)
  • Exclusion Criteria:
  • Currently taking medication for cardiac arrhythmia (e.g., beta blockers)
  • Currently in active treatment for breast cancer and/or other types of cancer
  • Currently pregnant

About King's College London

King's College London is a prominent research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the college leverages its extensive expertise in medicine, neuroscience, and public health to conduct rigorous studies aimed at improving patient outcomes. As a sponsor of clinical trials, King's College London prioritizes ethical standards, participant safety, and scientific integrity, fostering an environment that encourages groundbreaking research and the translation of findings into clinical practice. Through its state-of-the-art facilities and a diverse network of researchers, the institution strives to address critical health challenges and contribute to the global body of medical knowledge.

Locations

London, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Lauren C. Heathcote, PhD

Principal Investigator

King's College London

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported